Opinion
Volume 09:03, 2025

Reports in Thyroid Research

ISSN: 2684-4273

Open Access

Calcitonin, CGRP: Versatile Therapeutic Targets

Jonas Meier*

Department of Thyroid Cancer Research, Alpenheim Medical University, Zurich, Switzerland

Introduction

Calcitonin, a hormone long recognized for its role in regulating calcium levels, is now understood to possess a far broader spectrum of physiological actions beyond simple calcium homeostasis. While once a cornerstone for osteoporosis treatment, its role is now specific and limited, primarily for pain relief from vertebral fractures. It is not considered a first-line agent for increasing bone mineral density due to superior alternatives, but its analgesic properties and safety profile make it relevant in specific clinical scenarios, especially when other treatments are contraindicated or poorly tolerated. Its current primary application focuses on short-term use for acute pain [1].

This expanded understanding underscores calcitonin's versatility; recent research highlights its involvement in pain modulation, appetite regulation, inflammatory processes, and even neuroprotection, suggesting potential therapeutic applications beyond bone health and revealing its significant impact on various physiological systems through its widespread receptor distribution [4].

Furthermore, calcitonin is a well-established treatment for acute hypercalcemia, but emerging evidence suggests its therapeutic role extends beyond simple calcium reduction, involving processes like bone remodeling, renal calcium handling, and potentially pain perception. This multifaceted action implies potential underutilized applications or more nuanced approaches to its current use in managing elevated calcium levels [7].

The calcitonin receptor (CTR) and its intricate signaling pathways are critical for maintaining calcium homeostasis, yet their influence extends profoundly into various physiological and pathological states. This complex nature of CTR signaling, including its interaction with receptor activity-modifying proteins (RAMPs), holds significant implications for bone metabolism, inflammation, and pain. Understanding these signaling nuances is therefore essential for developing targeted therapies for conditions such as osteoporosis and chronic pain [5].

Intriguingly, the CTR plays a multifaceted role in various cancers, influencing cancer cell proliferation, migration, invasion, and even drug resistance. Exploring these complex signaling pathways involving CTR in different tumor types offers potential avenues for therapeutic targeting and prognostication in oncology, underscoring its significance as a potential biomarker or drug target [2].

Moreover, the CTR is increasingly recognized as a promising target for anti-inflammatory therapies. Beyond its role in bone metabolism, activation of CTR signaling pathways has demonstrated inhibitory effects on various inflammatory processes. This suggests that modulating CTR activity could offer a novel approach to managing inflammatory diseases, particularly those involving bone and cartilage degradation, by leveraging calcitonin's natural anti-inflammatory properties [8].

Furthermore, osteocytes, the most abundant bone cells, are now understood to be critical regulators of bone metabolism, and their interaction with calcitonin and its receptors is gaining significant attention. This nuanced role of calcitonin signaling within osteocytes suggests it influences not only bone formation and resorption but also processes like mechanotransduction, which could unlock new therapeutic strategies for bone diseases, moving beyond traditional targets [9].

Calcitonin gene-related peptide (CGRP) has emerged as a crucial neuropeptide with widespread implications, notably in the pathophysiology of migraine and cluster headache. Its established role in mediating neurogenic inflammation and pain signaling has led to the development of highly effective CGRP-targeting therapies, including monoclonal antibodies and small molecule antagonists. These treatments represent a significant advancement, offering new preventive and abortive options for patients suffering from these debilitating headache disorders by modulating CGRP pathways [3].

The advent of these CGRP-targeting drugs has indeed significantly reshaped the therapeutic landscape for migraine, particularly in light of evolving migraine classifications. These novel treatments, including monoclonal antibodies and gepants, offer targeted mechanisms to prevent and acutely treat migraine attacks by inhibiting CGRP pathways. Their efficacy and improved tolerability profiles provide valuable alternatives for patients, underscoring a paradigm shift in understanding and managing this complex neurological disorder [6].

Beyond its impact on headache disorders, CGRP also has significant implications in cardiovascular health and disease, acting as a potent vasodilator and modulator of cardiac function. Recent research explores its protective roles in conditions like hypertension, heart failure, and ischemia-reperfusion injury, alongside potential detrimental effects in others. A deeper understanding of CGRP's complex actions within the cardiovascular system could pave the way for novel diagnostic tools and targeted therapeutic interventions [10].

Description

Calcitonin, though no longer a primary agent for increasing bone mineral density in osteoporosis, maintains a specific and valuable role, particularly for acute pain relief arising from vertebral fractures [C001]. Its continued relevance in certain clinical scenarios, especially when alternative treatments are contraindicated or not tolerated, stems from its recognized analgesic properties and favorable safety profile. Beyond this specific application, a deeper understanding of calcitonin's physiological scope reveals its multifaceted nature. It is not merely a calcium-lowering hormone, but actively participates in pain modulation, appetite regulation,

and inflammatory processes [C004, C007]. This broader recognition highlights its versatility and potential for therapeutic applications extending beyond traditional bone health management, indicating its significant influence across various physiological systems due to its widespread receptor distribution [C004]. Its established efficacy in managing acute hypercalcemia is complemented by emerging evidence of its involvement in bone remodeling and renal calcium handling, suggesting previously underutilized therapeutic avenues [C007].

The Calcitonin Receptor (CTR) is a crucial mediator of calcitonin's diverse actions, extending its influence far beyond calcium homeostasis into a spectrum of physiological and pathological states. Its intricate signaling pathways are critical for maintaining calcium balance, but also profoundly impact bone metabolism, inflammation, and the perception of pain [C005]. Understanding these complex signaling nuances, including interactions with receptor activity-modifying proteins (RAMPs), is essential for developing targeted therapeutic strategies for conditions like osteoporosis and chronic pain. In oncology, research indicates the CTR plays a significant role in various cancers. Its expression can influence cancer cell proliferation, migration, invasion, and even drug resistance, positioning it as a potential biomarker or drug target through the exploration of its complex signaling pathways in different tumor types [C002].

Furthermore, the CTR is gaining recognition as a promising target for anti-inflammatory therapies. Studies demonstrate that activating CTR signaling pathways can exert inhibitory effects on various inflammatory processes [C008]. This discovery suggests a novel therapeutic approach to managing inflammatory diseases, particularly those involving bone and cartilage degradation, by leveraging calcitonin's inherent anti-inflammatory properties. Within bone tissue itself, osteocytes, which are the most abundant bone cells, are now understood to be critical regulators of bone metabolism. Their specific interactions with calcitonin and its receptors are attracting attention, with evidence suggesting an influence on bone formation, resorption, and mechanotransduction. Elucidating these cellular interactions could pave the way for innovative therapeutic strategies for bone diseases, moving beyond established targets [C009].

Calcitonin Gene-Related Peptide (CGRP) has emerged as a particularly important neuropeptide, especially within the field of neurology. It plays a pivotal role in the pathophysiology of both migraine and cluster headache by mediating neurogenic inflammation and pain signaling [C003]. This understanding has fundamentally transformed therapeutic approaches, leading to the development of highly effective CGRP-targeting treatments. These include monoclonal antibodies and small molecule antagonists, which offer significant advancements in both preventive and abortive options for patients suffering from these debilitating headache disorders by precisely modulating CGRP pathways [C003]. The impact of CGRP-targeting drugs is profound, reshaping the therapeutic landscape for migraine, especially in light of evolving classification systems [C006]. These novel agents provide targeted mechanisms to prevent and acutely treat migraine attacks, offering improved efficacy and tolerability, thereby marking a significant paradigm shift in how this complex neurological disorder is understood and managed [C006].

Beyond its neurological implications, CGRP also holds significant roles in cardiovascular health and disease. It is recognized as a potent vasodilator and an important modulator of cardiac function [C010]. Recent investigations are exploring both its protective roles in conditions such as hypertension, heart failure, and ischemia-reperfusion injury, as well as considering potential detrimental effects in other contexts. A deeper and more comprehensive understanding of CGRP's complex actions within the cardiovascular system is expected to pave the way for the development of novel diagnostic tools and highly targeted therapeutic interventions [C010].

Conclusion

Calcitonin, initially known for its role in calcium homeostasis, is now recognized for its diverse physiological actions, including pain modulation, appetite regulation, and anti-inflammatory processes. While its use in osteoporosis is limited, it remains valuable for pain relief from vertebral fractures, especially short-term when other treatments are contraindicated. The Calcitonin Receptor (CTR) plays a critical role beyond calcium regulation, influencing cancer cell proliferation, migration, and drug resistance, making it a potential biomarker and therapeutic target in oncology. CTR signaling is also crucial for bone metabolism, inflammation, and chronic pain, with its activation demonstrating inhibitory effects on inflammatory processes, suggesting its potential for anti-inflammatory therapies. Furthermore, Calcitonin Gene-Related Peptide (CGRP) is a key neuropeptide in migraine and cluster headache pathophysiology, mediating neurogenic inflammation and pain signaling. The development of CGRP-targeting therapies, such as monoclonal antibodies and small molecule antagonists, represents a significant advancement in treating these debilitating headache disorders. CGRP also holds implications for cardiovascular health, acting as a potent vasodilator and modulator of cardiac function, with both protective and potentially detrimental roles explored in conditions like hypertension and heart failure. Even within bone, osteocytes, the most abundant bone cells, are now understood to interact with calcitonin and its receptors, influencing bone formation, resorption, and mechanotransduction, which could lead to new therapeutic strategies for bone diseases. This expanding knowledge underscores the versatility of calcitonin, its receptor, and CGRP, offering new perspectives for diagnosis and targeted therapies across a spectrum of health conditions.

Acknowledgement

None.

Conflict of Interest

None.

References

1. René Rizzoli, Jean-Jacques Body, Maria Luisa Brandi. "Calcitonin for Osteoporosis: A Reappraisal." *Calcif Tissue Int* 104 (2019):639-650.
2. Venkatesh Ginjupalli, Panagiotis Basioukas, Sarkis Khoury. "Calcitonin receptor and its implications in cancer." *Semin Cancer Biol* 72 (2021):1-12.
3. Lars Edvinsson, Judit Tajti, Laszlo Vécsei. "Calcitonin Gene-Related Peptide as a Therapeutic Target for Migraine and Cluster Headache." *Pharmaceuticals* (Basel) 14 (2021):1178.
4. Madhushree Datta, Sanjay Varma, Suman Varma. "Calcitonin-A versatile hormone with diverse actions beyond calcium homeostasis." *J Bone Miner Metab* 40 (2022):917-927.
5. Dorit Naot, Karen E Callon, Greg D Gamble. "Calcitonin and Calcitonin Receptor Signaling in Health and Disease." *JBMR Plus* 7 (2023):e10756.
6. Tim De Vries, Paul Eekers, Theo Dekkers. "CGRP-targeting migraine drugs in the light of the new classification of migraine." *J Headache Pain* 20 (2019):81.
7. Takashi Koga, Shinsuke Nakajima, Keiji Ishikura. "Hypercalcemia and Calcitonin: More Than Just a Calcium-Lowering Hormone." *J Clin Med* 12 (2023):2546.

8. Dorit Naot, Karen E Callon, Catherine Coleman. "The calcitonin receptor as a potential target for anti-inflammatory therapies." *Br J Pharmacol* 178 (2021):1949-1961.
9. Morten A Karsdal, Kim Henriksen, Diana J Leeming. "Calcitonin and Calcitonin Receptors in Osteocytes: Current Perspectives and Future Directions." *J Bone Miner Res* 34 (2019):1631-1638.
10. Qian Mian, Ying Li, Yuanjie Lin. "Calcitonin gene-related peptide and cardiovascular disease: New perspectives." *Peptides* 166 (2023):171017.

How to cite this article: Meier, Jonas. "Calcitonin, CGRP: Versatile Therapeutic Targets." *Rep Thyroid Res* 09 (2025):124.

Address for Correspondence: Jonas, Meier, Department of Thyroid Cancer Research, Alpenheim Medical University, Zurich, Switzerland, E-mail: jonas.meier@alpenheim.ch

Received: 01-Sep-2025, Manuscript No. rtr-25-173554; **Editor assigned:** 03-Sep-2025, PreQC No. P-173554; **Reviewed:** 17-Sep-2025, QC No. Q-173554; **Revised:** 22-Sep-2025, Manuscript No. R-173554; **Published:** 29-Sep-2025, DOI: 10.37421/2684-4273.2025.9.124